ESR1 and neoplasm: They further demonstrated that anti-tumor efficacy with anti-PD-1 could be improved, indicated by reduced tumor burden, through inhibition of estrogen signaling, which was demonstrated by estrogen receptor deletion on macrophages or use of fulvestrant to block estrogen signaling123.